أعرض في EDS

Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area

التفاصيل البيبلوغرافية
العنوان: Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area
المؤلفون: Olivier Seror, Daniele Sommacale, Alain Luciani, Nathalie Ganne-Carrié, Pierre Balladur, Violaine Ozenne, Manon Allaire, Ailton Sepulveda, François Cauchy, Clémence Hollande, Giuliana Amaddeo, Lorraine Blaise, Hélène Regnault, Marco Dioguardi Burgio, François Paye, Mohamed Bouattour, Chetana Lim, Pierre-Philippe Massault, Vincent Leroy, Anthony Dohan, Edouard Larrey, Stanislas Pol, Françoise Roudot-Thoraval, Raffaele Brustia, Sanaa El Mouhadi, Olivier Scatton, Marie Lequoy, Valérie Vilgrain, Jean-Charles Nault
المساهمون: CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
المصدر: JHEP Reports, Vol 3, Iss 1, Pp 100199-(2021)
JHEP Reports Innovation in Hepatology
JHEP Reports Innovation in Hepatology, Elsevier, 2021, 3 (1), pp.100199. ⟨10.1016/j.jhepr.2020.100199⟩
JHEP Reports
بيانات النشر: Elsevier, 2021.
سنة النشر: 2021
مصطلحات موضوعية: Cirrhosis, Hepatocellular carcinoma, medicine.medical_treatment, TACE, Trans-arterial-chemo-embolization, Liver transplantation, law.invention, MTB, multi-disciplinary tumour board, MELD, Model for End stage Liver Disease, 0302 clinical medicine, Model for End-Stage Liver Disease, Interquartile range, law, Immunology and Allergy, OR, Odd Ratio, AP-HP, Assistance Publique-Hôpitaux de Paris, BCLC, Barcelona Clinic Liver Cancer, Gastroenterology, ICU, intensive care unit, Intensive care unit, 3. Good health, Management, 030220 oncology & carcinogenesis, 2019-nCoV, 030211 gastroenterology & hepatology, medicine.medical_specialty, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, LT, liver transplantation, Article, AFP, Alpha-fetoprotein, 03 medical and health sciences, IR, interventional radiology, Internal medicine, Internal Medicine, medicine, lcsh:RC799-869, IQR, interquartile range, Intention-to-treat analysis, Hepatology, AFEF, Societé Francaise d’Hépatologie, business.industry, COVID-19, SIRT, Selective internal radiation therapy, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Odds ratio, medicine.disease, PCR-RT, PCR real time, aOR, adjusted OR, CI, Confidence Interval, digestive system diseases, ITT, intention to treat, LR, liver resection, CT, computerized-tomography, EASL, European Association of Study of Liver, lcsh:Diseases of the digestive system. Gastroenterology, HCC, hepatocellular carcinoma, business
الوصف: Background Patients affected by HCC represent a vulnerable population during the COVID-19 pandemic and may suffer from the unusual allocation of healthcare resources. The aim of this study was to determine the impact of the COVID-19 pandemic on the management of HCC patients within six French referral centers of the metropolitan area of Paris. Materials and methods We performed a multicenter, retrospective, cross-sectional study on the management of patients affected by HCC during the first six weeks of COVID-19 pandemic (exposed), compared to the same period in 2019 (unexposed). Were included all patients discussed in multidisciplinary tumor meeting (MTB) and/or undergoing radiological or surgical programmed procedure during the study period, in a curative or palliative intent. Endpoints were the number of patients with a modification in the treatment strategy, or a delay in decision-to-treatment. Results After screening, n=670 patients were included (n=293 Exposed to COVID, n=377 Unexposed to COVID). A decrease of the numbers of patients with HCC presented in MTB in 2020 (p=0.034) and with a first diagnosis of HCC (n=104 Exposed to COVID, n=143 Unexposed to COVID, p=0.083) was find. Modification in the treatment strategy was observed in 13.1% of patients, with no differences between the two periods. Nevertheless 21.5% versus 9.5% of patients experienced a treatment delay longer than 1 month in 2020 compared to 2019 (p
Graphical abstract
Highlights • In COVID period, a decrease of the numbers of patients with hepatocellular carcinoma presented in Multidisciplinary Tumour Board and, in particular, with a first diagnosis of HCC was find. • Globally, modification in the treatment strategy was observed in 13.1% of patients, with no differences between the two periods but the main reason was significantly different in 2020 compared to 2019: COVID-19 in 2020 vs tumour progression in 2019. • More than 21% of patients experienced a treatment delay longer than 1 month in COVID period compared to 9.5% in 2019 , specially, in subgroup with active, recurrent HCC. The main reasons for the delay of treatment in 2020 was COVID-19 infection related • In 2020, 7.1% of patients had a diagnosis of an active COVID-19 infection and 4/21 (19.1%) died.
During COVID pandemic era, less patients with hepatocellular carcinoma (HCC) have been presented in multidisciplinary tumor bord, specially with a first diagnosis of HCC
اللغة: English
تدمد: 2589-5559
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::996648113d3806dc05e75ca8edbba8b3
http://www.sciencedirect.com/science/article/pii/S2589555920301336
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....996648113d3806dc05e75ca8edbba8b3
قاعدة البيانات: OpenAIRE
الوصف
تدمد:25895559